1515
Annons
Elicera Therapeutics: BioStock: Elicera continues to deliver proof-of-concept data

Swedish cell and gene therapy company Elicera Therapeutics has achieved preclinical proof-of-concept in two of its immuno-oncology projects. iTANK, a universal CAR T-cell enhancement technology platform, reached proo-of-concept late last year, and the data was published in a high impact journal earlier this month.  Most recently, Elicera announced concluding proof-of-concept studies with ELC-201, a next-generation oncolytic virus aimed at treating a wide range of tumour indications.

Read the article at biostock.se:

https://www.biostock.se/en/2022/04/elicera-continues-to-deliver-proof-of-concept-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera